US equities |
SPCX $168.44 ▲+5.97% NVDA $237.25 ▲+1.41% MU $1,065.97 ▼-0.83% TSLA $378.22 ▲+2.06% MSFT $525.98 ▲+1.63% INTC $116.93 ▼-2.01% SNDK $1,722.17 ▲+0.13% META $745.49 ▲+2.39%
FinancialContent

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

73.88 +0.88 (+1.20%)
Delayed Quote Updated: 11:05 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Combines High-Growth Momentum with a Favorable Technical Setup ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Tarsus Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout ↗
Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors. 
Via Chartmill
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗
Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential. 
Via Chartmill
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗
Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase 
Via The Motley Fool
News headline image
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
3 Biotech Catalysts Present Major Opportunity ↗
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗
 
Via Benzinga
News headline image
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
News headline image
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >